Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 24, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01309737
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 24, 2026, 7:04 AM EDT
Terminated Phase 3 Interventional Results available

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

NCT03626545
View directory record Official record
Conditions
Non-Small-Cell Lung
Interventions
Canakinumab, Docetaxel, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 24, 2026, 7:04 AM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 24, 2026, 7:04 AM EDT
Recruiting Phase 2 Interventional

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

NCT04499053
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 24, 2026, 7:04 AM EDT
Terminated No phase listed Observational

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

NCT02715102
View directory record Official record
Conditions
Cancer of the Lung, Lung Cancer, Lung Neoplasms, Adenocarcinoma of the Lung, Non Small Cell Carcinoma of the Lung, Small Cell Carcinoma of the Lung
Interventions
Not listed
Lead sponsor
Pathway Genomics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 24, 2026, 7:04 AM EDT
Completed No phase listed Observational

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT01026467
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cisplatin, carboplatin, questionnaire administration
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Syracuse, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 24, 2026, 7:04 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00003111
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, irinotecan hydrochloride, paclitaxel, neoadjuvant therapy, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 24, 2026, 7:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
Interventions
177Lu-BetaBart, BetaBart + unlabeled BetaBart
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 7:04 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
31
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 24, 2026, 7:04 AM EDT
Completed Not applicable Interventional Results available

Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD

NCT03935932
View directory record Official record
Conditions
COPD
Interventions
nasal delivery of heated and humidified air
Device
Lead sponsor
Frank C Sciurba
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 24, 2026, 7:04 AM EDT
Completed No phase listed Observational

Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea

NCT02097212
View directory record Official record
Conditions
Trachebronchomalacia (TBM), Hyper Dynamic Airway Collapse (HDAC), Obstructive Sleep Apnea (OSA)
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 24, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 24, 2026, 7:04 AM EDT
Terminated Phase 3 Interventional Results available

A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

NCT01218009
View directory record Official record
Conditions
Asthma
Interventions
Placebo Spiromax, Albuterol Spiromax
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 24, 2026, 7:04 AM EDT
Completed No phase listed Observational

Registry of Asthma Patients Initiating DUPIXENT®

NCT04287621
View directory record Official record
Conditions
Asthma
Interventions
DUPIXENT®
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
73
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 24, 2026, 7:04 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

NCT07871214
View directory record Official record
Conditions
Early-Stage Non-Small Cell Lung Cancer
Interventions
Pumitamig, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 7:04 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

NCT02382406
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Carboplatin, Nab-paclitaxel, MK-3475 (Phase I), MK-3475 (Phase II)
Drug
Lead sponsor
Nisha Mohindra, MD
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 24, 2026, 7:04 AM EDT
Completed Phase 1 Interventional

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 24, 2026, 7:04 AM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 24, 2026, 7:04 AM EDT
Terminated Phase 2 Interventional Results available

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

NCT04323436
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Spartalizumab, Capmatinib, spartalizumab placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 24, 2026, 7:04 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

NCT06033833
View directory record Official record
Conditions
Asthma
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Stockton, California • Boynton Beach, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 7:04 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT04625647
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Sotorasib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
828
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 561 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 24, 2026, 7:04 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

NCT01798485
View directory record Official record
Conditions
Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions
Docetaxel, Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
78
States / cities
Flagstaff, Arizona • Prescott Valley, Arizona • Sedona, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 24, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)

NCT00200967
View directory record Official record
Conditions
Asthma
Interventions
salmeterol, beclomethasone HFA
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 7:04 AM EDT